カテゴリ： GlobalData, アメリカ, 企業調査

SR One Ltd-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：SR One Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013279
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月28日
◆ページ数：127
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
SR One Ltd (SR One), a subsidiary of GlaxoSmithKline Plc is a venture capital firm that offers investment services for seed, start up, early and mid venture; and emerging growth companies. The firm invests globally in emerging life science companies that are pursuing innovative science which significantly impacts medical care with products in preclinical development stage through clinical proof-of-concept; biotechnology; healthcare; medical devices, and related information technologies companies. It operates through its investment teams located in the US and the UK. The firm has operations in Cambridge, Conshohocken, London and San Francisco. SR One is headquartered in Conshohocken, Pennsylvania, the US.

SR One Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
SR One Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
SR One Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
SR One Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
SR One Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
SR One Ltd, Medical Devices Deals, 2011 to YTD 2017 12
SR One Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
SR One Ltd, Pharmaceuticals & Healthcare, Deal Details 23
Venture Financing 23
Palleon Pharma Raises USD47.6 Million in Series A Financing 23
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 24
Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 26
TP Therapeutics Raises USD45 Million in Series C Financing 28
Pulmocide Raises USD30.4 Million in Series B Financing 29
Spero Therapeutics Raises USD51.7 Million in Series C Financing 31
Tioma Therapeutics Raises USD86 Million in Series A Financing 33
Second Genome Raises USD8.4 Million in Extended Series B Financing 34
Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 35
Spero Therapeutics to Raise USD30 Million in Series B Preferred Financing 36
Mission Therapeutics Raises USD85.7 Million in Financing Round 37
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 39
Navitor Pharma Raises USD33 Million in Series B Financing 41
Constellation Pharma Raises USD55 Million Financing 43
True North Therapeutics Raises USD40 Million in Series C Financing 45
Decibel Therapeutics Raises USD52 Million in Series A Financing Round 47
Asceneuron Raises USD30.6 Million in Series A Financing 48
Gladius Pharma Raises USD3.3 Million in Series A Financing 50
Atopix Therapeutics Raises Additional Funds through Venture Financing 51
Spero Therapeutics Raises USD30 Million in Extended Series A Financing 52
PsiOxus Therapeutics Raises USD39.2 Million in Series C Financing 53
CRISPR Therapeutics Raises Additional USD35 Million in Series A Financing 55
CRISPR Therapeutics Raises USD29 Million in Series B Financing 57
ZappRx Raises USD5.6 Million in Series A Financing 59
Thrasos Therapeutics Raises USD21 Million in Series D Financing 60
Nimbus Therapeutics Raises USD43 Million in Series B Financing 62
Macrolide Pharma Raises USD22 Million in Series A Financing 63
Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 64
Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 66
Atopix Therapeutics Raises Funds through Extended Series A Financing 67
Atox Bio Raises up to USD23 Million in Series E Venture Financing 68
Navitor Pharma Raises USD24 Million in Series A Financing 69
True North Therapeutics Raises USD22 Million in Series A Venture Financing 71
Principia Biopharma Raises US$50 Million In Series B Venture Financing 73
Spero Therapeutics Raises USD3 Million in Series A Venture Financing 75
Alios BioPharma Raises US$41 Million In Series B Venture Financing 76
RuiYi Raises US$15 Million In Series B Financing 77
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 79
VHsquared Secures Series A Funding Round 80
Aileron Therapeutics Raises US$30 Million In Series E Financing 81
Mission Therapeutics Raises US$32 Million In Series B Financing 83
F-Star Alpha Raises US$13 Million In Series A Financing 84
iPierian Raises US$30 Million In Series A Venture Financing 85
Effector Therapeutics Raises US$45 Million In Series A Financing 87
Progenitor Labs Raises US$5.8 Million In Seed Financing 89
Aileron Raises US$12 Million In Extended Series D Financing 90
River Vision Development Raises US$17 Million In Series A Financing 92
Bicycle Therapeutics Raises US$6 Million In Venture Financing 93
Applied Genetic Technologies Raises US$37.5 Million In Series B Financing 95
HTG Molecular Diagnostics Raises US$7.5 Million In Series E Financing 97
Thrasos Therapeutics Raises US$35 Million In Venture Financing 98
SR One Plans To Invest In Biotechnology Company 100
Genocea Biosciences Raises US$30 Million In Series C Financing 101
Principia Biopharma Raises Additional US$13 Million In Series A Financing 103
PsiOxus Therapeutics Raises Additional US$34 Million In Series B Financing 105
RaNA Therapeutics Raises Additional US$18 Million In Series A Financing 107
Mission Therapeutics Raises US$10 Million In Series A Financing 109
Nimbus Discovery Secures US$24 Million In Series A Financing 110
High Throughput Genomics Secures US$0.5 Million In Second Closing Of Series D Venture Round 111
Constellation Pharma Secures Additional US$15 Million In Series B Financing 112
f-star Secures US$21.7 Million In Financing Round 114
Principia Biopharma Raises US$12 Million In First Tranche Of Series A Financing 116
Genocea Biosciences Secures US$35 Million In Series B Venture Financing 117
Acquisition 119
Ipsen Acquires Syntaxin, Life Sciences Company, For US$206 Million 119
SuperGen Completes Acquisition Of Astex Therapeutics 121
SR One Ltd – Key Competitors 124
SR One Ltd – Key Employees 125
SR One Ltd – Locations And Subsidiaries 126
Head Office 126
Other Locations & Subsidiaries 126
Appendix 127
Methodology 127
About GlobalData 127
Contact Us 127
Disclaimer 127

List of Tables
SR One Ltd, Pharmaceuticals & Healthcare, Key Facts 2
SR One Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
SR One Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
SR One Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
SR One Ltd, Deals By Therapy Area, 2011 to YTD 2017 10
SR One Ltd, Medical Devices Deals, 2011 to YTD 2017 12
SR One Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Palleon Pharma Raises USD47.6 Million in Series A Financing 23
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 24
Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 26
TP Therapeutics Raises USD45 Million in Series C Financing 28
Pulmocide Raises USD30.4 Million in Series B Financing 29
Spero Therapeutics Raises USD51.7 Million in Series C Financing 31
Tioma Therapeutics Raises USD86 Million in Series A Financing 33
Second Genome Raises USD8.4 Million in Extended Series B Financing 34
Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 35
Spero Therapeutics to Raise USD30 Million in Series B Preferred Financing 36
Mission Therapeutics Raises USD85.7 Million in Financing Round 37
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 39
Navitor Pharma Raises USD33 Million in Series B Financing 41
Constellation Pharma Raises USD55 Million Financing 43
True North Therapeutics Raises USD40 Million in Series C Financing 45
Decibel Therapeutics Raises USD52 Million in Series A Financing Round 47
Asceneuron Raises USD30.6 Million in Series A Financing 48
Gladius Pharma Raises USD3.3 Million in Series A Financing 50
Atopix Therapeutics Raises Additional Funds through Venture Financing 51
Spero Therapeutics Raises USD30 Million in Extended Series A Financing 52
PsiOxus Therapeutics Raises USD39.2 Million in Series C Financing 53
CRISPR Therapeutics Raises Additional USD35 Million in Series A Financing 55
CRISPR Therapeutics Raises USD29 Million in Series B Financing 57
ZappRx Raises USD5.6 Million in Series A Financing 59
Thrasos Therapeutics Raises USD21 Million in Series D Financing 60
Nimbus Therapeutics Raises USD43 Million in Series B Financing 62
Macrolide Pharma Raises USD22 Million in Series A Financing 63
Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 64
Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 66
Atopix Therapeutics Raises Funds through Extended Series A Financing 67
Atox Bio Raises up to USD23 Million in Series E Venture Financing 68
Navitor Pharma Raises USD24 Million in Series A Financing 69
True North Therapeutics Raises USD22 Million in Series A Venture Financing 71
Principia Biopharma Raises US$50 Million In Series B Venture Financing 73
Spero Therapeutics Raises USD3 Million in Series A Venture Financing 75
Alios BioPharma Raises US$41 Million In Series B Venture Financing 76
RuiYi Raises US$15 Million In Series B Financing 77
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 79
VHsquared Secures Series A Funding Round 80
Aileron Therapeutics Raises US$30 Million In Series E Financing 81
Mission Therapeutics Raises US$32 Million In Series B Financing 83
F-Star Alpha Raises US$13 Million In Series A Financing 84
iPierian Raises US$30 Million In Series A Venture Financing 85
Effector Therapeutics Raises US$45 Million In Series A Financing 87
Progenitor Labs Raises US$5.8 Million In Seed Financing 89
Aileron Raises US$12 Million In Extended Series D Financing 90
River Vision Development Raises US$17 Million In Series A Financing 92
Bicycle Therapeutics Raises US$6 Million In Venture Financing 93
Applied Genetic Technologies Raises US$37.5 Million In Series B Financing 95
HTG Molecular Diagnostics Raises US$7.5 Million In Series E Financing 97
Thrasos Therapeutics Raises US$35 Million In Venture Financing 98
SR One Plans To Invest In Biotechnology Company 100
Genocea Biosciences Raises US$30 Million In Series C Financing 101
Principia Biopharma Raises Additional US$13 Million In Series A Financing 103
PsiOxus Therapeutics Raises Additional US$34 Million In Series B Financing 105
RaNA Therapeutics Raises Additional US$18 Million In Series A Financing 107
Mission Therapeutics Raises US$10 Million In Series A Financing 109
Nimbus Discovery Secures US$24 Million In Series A Financing 110
High Throughput Genomics Secures US$0.5 Million In Second Closing Of Series D Venture Round 111
Constellation Pharma Secures Additional US$15 Million In Series B Financing 112
f-star Secures US$21.7 Million In Financing Round 114
Principia Biopharma Raises US$12 Million In First Tranche Of Series A Financing 116
Genocea Biosciences Secures US$35 Million In Series B Venture Financing 117
Ipsen Acquires Syntaxin, Life Sciences Company, For US$206 Million 119
SuperGen Completes Acquisition Of Astex Therapeutics 121
SR One Ltd, Key Competitors 124
SR One Ltd, Key Employees 125
SR One Ltd, Other Locations 126

★海外企業調査レポート[SR One Ltd-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Hatch Ltd：企業の戦略的SWOT分析
    Hatch Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Herantis Pharma Plc (HRTIS)：医療機器：M&Aディール及び事業提携情報
    Summary Herantis Pharma Plc (Herantis Pharma) is a drug development company that offers regenerative medicine for neurodegenerative diseases. The company's pipeline products include CDNF for amyotrophic lateral sclerosis, CDNF for Parkinson’s disease and lymfactin for secondary lymphedema. Its lymfa …
  • Boral Limited：企業の戦略・SWOT・財務情報
    Boral Limited - Strategy, SWOT and Corporate Finance Report Summary Boral Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Chiyoda Corp (6366)：企業の財務・戦略的SWOT分析
    Chiyoda Corp (6366) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Par Pacific Holdings, Inc. (PARR)-石油・ガス分野：企業M&A・提携分析
    Summary Par Pacific Holdings, Inc. (Par Pacific), formerly known as Par Petroleum Corporation, manages, owns and maintains interests in energy and infrastructure related businesses. It has operations across the value chain from natural gas production to distribution and transportation. The company c …
  • Tandem Diabetes Care Inc (TNDM)：企業の製品パイプライン分析
    Summary Tandem Diabetes Care Inc (Tandem) is a medical device manufacturing company that designs and develops diabetic care products. The company's product portfolio includes t:slim X2 insulin pump, basal-IQ technology, software and applications, infusion sets and other pump accessories. It also pro …
  • Curetis NV (CURE)-医療機器分野：企業M&A・提携分析
    Summary Curetis NV (Curetis) is a medical device company that offers molecular diagnosis solutions. The company offers diagnostic systems developed with Unyvero platform for severe infectious diseases. Its products are used in rapid diagnosis for variety of cartridges, diseases such as pneumonia, im …
  • Verastem Inc (VSTM)：企業の財務・戦略的SWOT分析
    Summary Verastem Inc (Verastem) is a clinical-stage biopharmaceutical company with focus on the discovery, development and commercialization of drugs to treat cancer. The company’s lead product candidates include duvelisib, defactinib (VS-6063), FAK inhibitor (VS-4718) and PI3K/mTOR inhibitor (VS-55 …
  • Pathway Genomics Corp：医療機器：M&Aディール及び事業提携情報
    Summary Pathway Genomics Corp (Pathway Genomics) is a healthcare laboratory that offers genetic testing services. Its tests comprise liquid biopsy cancer intercept, true hereditary cancer genetic tests, DNA insight general health and wellness genetic tests, DNA insight pharmacogenomics tests, and ca …
  • Axela Inc：製品パイプライン分析
    Summary Axela Inc (Axela), formerly Axela Biosensors Inc is a provider of optic technology solutions. The company offers Ziplex system, Flow-thru TipChips, panelPlus TipChips, diffractive optics technology, diffractive optics sensors, panelPlus sensors and software products. It offers technical and …
  • Stock Spirits Group PLC：企業の戦略・SWOT・財務情報
    Stock Spirits Group PLC - Strategy, SWOT and Corporate Finance Report Summary Stock Spirits Group PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Tethys Oil AB (TETY)：石油・ガス：M&Aディール及び事業提携情報
    Summary Tethys Oil AB (Tethys Oil) is an upstream oil and gas company that offers exploration, development and production of oil and natural gas reserves. The company holds 2P reserves of 21.4 mmbo and has an oil production of barrels from Blocks in Sultanate of Oman. It also holds onshore explorati …
  • Provogue (India) Limited (PROVOGE)：企業の財務・戦略的SWOT分析
    Provogue (India) Limited (PROVOGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • NorthWestern Corporation (NWE)：石油・ガス：M&Aディール及び事業提携情報
    Summary NorthWestern Corp, doing business as NorthWestern Energy, is an electric and natural gas utility. It generates, transmits, and electricity, and also carries out mid-stream operations. The company produces from wind, hydro, solar, coal, and natural gas. NorthWestern Energy produces, stores, t …
  • Chevron Corp (CVX)：企業の財務・戦略的SWOT分析
    Chevron Corp (CVX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Warner Media LLC：企業の戦略的SWOT分析
    Warner Media LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Genera Biosystems Ltd (GBI)：企業の財務・戦略的SWOT分析
    Summary Genera Biosystems Ltd (GBL) is a multiplexed molecular diagnostic testing product developer. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pathogens; and PapType is …
  • Votorantim Energia Ltda：企業の戦略的SWOT分析
    Votorantim Energia Ltda - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Olvi plc：企業の戦略・SWOT・財務情報
    Olvi plc - Strategy, SWOT and Corporate Finance Report Summary Olvi plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Standard Chartered Bank – India Branches：企業の戦略・SWOT・財務情報
    Standard Chartered Bank – India Branches - Strategy, SWOT and Corporate Finance Report Summary Standard Chartered Bank – India Branches - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆